Open Access

The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection

  • Authors:
    • Kosuke Matsumoto
    • Hisamitsu Miyaaki
    • Masanori Fukushima
    • Ryu Sasaki
    • Masafumi Haraguchi
    • Satoshi Miuma
    • Kazuhiko Nakao
  • View Affiliations

  • Published online on: December 7, 2021     https://doi.org/10.3892/br.2021.1492
  • Article Number: 9
  • Copyright: © Matsumoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Single‑nucleotide polymorphisms (SNPs) of patatin‑like phospholipase domain‑containing 3 (PNPLA3), tolloid‑like protein 1 (TLL1) and interleukin‑28 (IL28) have been identified as susceptibility factors for liver steatosis, inflammation and fibrosis in patients with hepatitis C virus (HCV) infection. Here, whether these polymorphisms affected predispositions to changes in liver stiffness (LS) and controlled attenuation parameter (CAP) following direct‑acting antiviral (DAA) therapy was assessed. The changes in LS and steatosis in 77 HCV‑infected patients receiving DAA therapy were compared with PNPLA3, TLL1 and IL28 genotypes, using CAP, FibroScan and Virtual Touch tissue quantification (VTTQ) before treatment and 12 weeks after the end of the treatment. VTTQ results showed that LS significantly decreased in PNPLA3 CC (P=0.035), TLL1 AA (P=0.011) and IL28B TT (P=0.005) genotypes; no significant differences were observed in PNPLA3 CG/GG, TLL1 AT/TT and IL28B TG/GG. FibroScan results showed that LS significantly decreased in TLL1 AA (P=0.028) and IL28B TT (P=0.032), with no significant difference in PNPLA3 CC. No significant differences were observed in PNPLA3 CG/GG, TLL1 AT/TT and IL28B TG/GG groups. CAP was significantly increased in PNPLA3 CG/GG (P=0.039 and P<0.05) and IL28B TT (P=0.014); no significant difference was observed in PNPLA3 CC and all genotypes of TLL1 and IL28B TG/GG. Therefore, these results indicated that SNPs could predict changes in LS and steatosis after DAA therapy.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 16 Issue 2

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsumoto K, Miyaaki H, Fukushima M, Sasaki R, Haraguchi M, Miuma S and Nakao K: The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection. Biomed Rep 16: 9, 2022
APA
Matsumoto, K., Miyaaki, H., Fukushima, M., Sasaki, R., Haraguchi, M., Miuma, S., & Nakao, K. (2022). The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection. Biomedical Reports, 16, 9. https://doi.org/10.3892/br.2021.1492
MLA
Matsumoto, K., Miyaaki, H., Fukushima, M., Sasaki, R., Haraguchi, M., Miuma, S., Nakao, K."The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection". Biomedical Reports 16.2 (2022): 9.
Chicago
Matsumoto, K., Miyaaki, H., Fukushima, M., Sasaki, R., Haraguchi, M., Miuma, S., Nakao, K."The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection". Biomedical Reports 16, no. 2 (2022): 9. https://doi.org/10.3892/br.2021.1492